ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 224

Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study

Angelo L. Gaffo1, Nicola Dalbeth2, Kenneth G. Saag3, Jasvinder Singh3, Elizabeth J. Rahn1, Amy S. Mudano3, Tuhina Neogi4, Lorenzo Cavagna5, Yi-Hsing Chen6, Ching-Tsai Lin7, Worawit Louthrenoo8, Geraldo Castelar-Pinheiro9, Fernando Perez-Ruiz10, Janitzia Vazquez-Mellado11, Maxim Eliseev12, Lisa K. Stamp13 and William Taylor14, 1Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Auckland, Auckland, New Zealand, 3University of Alabama at Birmingham, Birmingham, AL, 4Boston University School of Medicine, Boston, MA, 5Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 6Taichung Veterans General Hospital, Taichung, Taiwan, 7Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, 8Div of Rheumatology, Dept of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, 9Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil, 10Servicio de Reumatología, Vizcaya, Spain, 11Rheumatology, Hospital General de México, Mexico City, Mexico, 12Research Institute of Rheumatology of Russia, Moscow, Russian Federation, 13University of Otago, Christchurch, New Zealand, 14University of Otago, Wellington, New Zealand

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: gout, outcomes, pain and quality of life

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Patient Perception of Gout Flares as a Measure of Outcome:

Results from an International Study

Background/Purpose: Attacks (flares) are one of the primary manifestations of gout. It is not known how infrequently gout flares need to occur for patients to consider their disease to be in remission, in a state of low activity (LDA), or in an acceptable state (PASS). In addition, it is not clear what time horizon should be used to determine these disease activity states. The aim of this study is to estimate the patient-perceived frequency of gout flares associated with disease activity states along with a clear time-horizon for these estimates

Methods: We enrolled 374 individuals with gout from 15 international sites in a cross-sectional study. We inquired about flare frequencies in the past 6 and 12 months and actual and hypothetical perception of disease states: remission (“gout is gone”), LDA (“gout control is satisfactory”) or acceptable state (“gout requires no more treatment”) with relation to flares. Data from one half of the group (discovery group) was used to estimate the best discriminatory cutpoints to distinguish remission vs. non-remission, LDA vs. no-LDA, and PASS vs. no-PASS using logistic regression. We then applied these estimates to the second half of the group (validation group) to calculate sensitivity and specificity of these thresholds. Results at 6 and 12-month recollection intervals were compared. Results: The mean age of participants was 52.7 years (SD 13.9), 90.2% were men, and 33.2% had tophi. Participants reported experiencing a median of 2 (IQR 0-4) and 3 (IQR 1-8) flares in the 6- and 12-month preceding period, respectively. From the flare perspective, 24.5% of and 22.6% of participants reported that their gout was in remission.  Flare frequency thresholds for disease states were lower with asking the participants about hypothetical (imagined) scenarios than when with their past recollection of disease states within the validation cohort (Table). Recollection of one flare or less in the prior 6 and 12 month periods provided the best predictive cutpoints between a between being or no being in remission, LAD, or PASS (Table).  Responses at 6 and 12 months had comparable performance.

Conclusion:   Recollection of one flare or less in the previous 6-month period provides the best discrimination for patient-reported gout flare remission state, although the diagnostic performance of this threshold is limited.  A 12-month recall period does not outperform a 6-month recall period for assessing gout flare disease states.

 


Disclosure: A. L. Gaffo, Cymabay, 5,AstraZeneca, 5,REVIVE, 5,AstraZeneca, 2; N. Dalbeth, AstraZeneca, 2,Takeda, 5,Crealta, 5,Cymabay, 5,AstraZeneca, 5,AstraZeneca, 9; K. G. Saag, Ardea/AstraZeneca, 5,Crealta, 5,Takeda, 5,Ardea/AstraZeneca, 2,Crealta, 2,Takeda, 2; J. Singh, Takeda Pharmaceuticals, Savient, 2,Savient, Takeda, Horizon, Regeneron, Merz, Iroko, Bioiberica, Crealta, Allergan, WebMD, UBM LLC, ACR, 5; E. J. Rahn, None; A. S. Mudano, None; T. Neogi, None; L. Cavagna, None; Y. H. Chen, None; C. T. Lin, None; W. Louthrenoo, None; G. Castelar-Pinheiro, None; F. Perez-Ruiz, None; J. Vazquez-Mellado, None; M. Eliseev, None; L. K. Stamp, None; W. Taylor, None.

To cite this abstract in AMA style:

Gaffo AL, Dalbeth N, Saag KG, Singh J, Rahn EJ, Mudano AS, Neogi T, Cavagna L, Chen YH, Lin CT, Louthrenoo W, Castelar-Pinheiro G, Perez-Ruiz F, Vazquez-Mellado J, Eliseev M, Stamp LK, Taylor W. Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/patient-perception-of-gout-flares-as-a-measure-of-outcome-results-from-an-international-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-perception-of-gout-flares-as-a-measure-of-outcome-results-from-an-international-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology